a developer of novel oral antiviral therapeutics
Industry Biotechnology
A.I.dvisor tells us that CMRX and DNA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMRX and DNA's prices will move in lockstep.
Ticker / NAME | Correlation To CMRX | 1D Price Change % | ||
---|---|---|---|---|
CMRX | 100% | -5.40% | ||
DNA - CMRX | 30% Poorly correlated | -15.00% | ||
MDGL - CMRX | 28% Poorly correlated | -3.96% | ||
STRO - CMRX | 28% Poorly correlated | -12.88% | ||
KRYS - CMRX | 28% Poorly correlated | -3.71% | ||
CRBU - CMRX | 27% Poorly correlated | -5.00% | ||
More |
Ticker / NAME | Correlation To CMRX | 1D Price Change % |
---|---|---|
CMRX | 100% | -5.40% |
drugs theme (254 stocks) | 21% Poorly correlated | -4.03% |
therapeutics theme (53 stocks) | 17% Poorly correlated | -5.73% |
oral products theme (5 stocks) | 10% Poorly correlated | -2.87% |
biotechnology theme (238 stocks) | 5% Poorly correlated | -4.32% |